All In Biotech

NDA 207070 · Boehringer Ingelheim

Spiriva Respimat

Tiotropium Bromide · Inhalation

Last checked: Nov 20, 2026Latest source record: Sep 15, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Sep 15, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

347

124 Phase 3, 2 recruiting

FAERS reports

11,487

6,855 serious, 778 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 17, 2026.

SPIRIVA RESPIMAT is an anticholinergic indicated for: The long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations ( 1.1 ) The long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older ( 1.2 ) Limitation of Use: Not indicated for relief of acute bronchospasm ( 1.1 , 1.2 , 5.1 ) 1.1 Maintenance Treatment of Chronic Obstructive Pulmonary Disease SPIRIVA RESPIMAT (tiotropium bromide) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. SPIRIVA RESPIMAT is indicated to reduce exacerbations in COPD patients. Important Limitation of Use: SPIRIVA RESPIMAT is NOT indicated for the relief of acute bronchospasm. 1.2 Maintenance Treatment of Asthma SPIRIVA RESPIMAT is a bronchodilator indicated for the long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older . Important Limitation of Use: SPIRIVA RESPIMAT is NOT indicated for the relief of acute bronchospasm.

Mechanism: Tiotropium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M 1 to M 5 . In the airways, it exhibits pharmacological effects through inhibition of M 3 -receptors at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine-induced bronchoconstriction effects was dose-dependent and lasted...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SPIRIVA RESPIMAT · TIOTROPIUM BROMIDE 2.5MCG · SPRAY, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tiotropium" as an intervention, any sponsor and status, largest first.

All 347 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea2,340
  • asthma1,510
  • cough1,093
  • pneumonia934
  • wheezing846
  • drug ineffective771
  • off label use716
  • therapeutic product effect incomplete581
  • chronic obstructive pulmonary disease570
  • loss of personal independence in daily activities520
  • fatigue508
  • headache469

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20083
20093
201013
201124
201242
201375
201431
201550
2016121
2017418
20181,080
20191,223
20201,652
20211,213
20221,006
20231,000
20241,273
20251,209
20261,051

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Spiriva Respimat (Tiotropium Bromide)

2024 spending

$877M

Beneficiaries

327,575

1,276,042 claims

Per beneficiary

$2,678

$119.52 per unit

View as table
YearSpending
2020$804,565,194
2021$856,830,826
2022$891,532,179
2023$923,556,171
2024$877,208,066

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 588 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.